BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 11,698 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 11,698 shares of the firm’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $298.34, for a total transaction of $3,489,981.32. Following the completion of the transaction, the chief executive officer owned 11,698 shares of the company’s stock, valued at approximately $3,489,981.32. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The stock was sold at an average price of $304.35, for a total transaction of $14,767,062.00.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The shares were sold at an average price of $305.95, for a total transaction of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The shares were sold at an average price of $273.78, for a total transaction of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total transaction of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total transaction of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The stock was sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Stock Performance

NASDAQ ONC opened at $306.56 on Wednesday. The company has a market capitalization of $33.64 billion, a price-to-earnings ratio of 68.58 and a beta of 0.49. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $253.95 and a twelve month high of $385.22. The stock has a fifty day simple moving average of $290.24 and a 200 day simple moving average of $308.90.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Sell-side analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 EPS for the current year.

Institutional Trading of BeOne Medicines

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cetera Investment Advisers acquired a new position in BeOne Medicines during the 2nd quarter worth approximately $455,000. Rhumbline Advisers acquired a new stake in BeOne Medicines in the second quarter valued at approximately $275,000. Arrowstreet Capital Limited Partnership bought a new stake in shares of BeOne Medicines during the second quarter valued at approximately $505,000. Invesco Ltd. bought a new stake in shares of BeOne Medicines during the second quarter valued at approximately $422,000. Finally, EverSource Wealth Advisors LLC acquired a new position in shares of BeOne Medicines during the second quarter worth approximately $68,000. 48.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

ONC has been the subject of a number of recent analyst reports. Zacks Research downgraded shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 3rd. Truist Financial boosted their price target on shares of BeOne Medicines from $413.00 to $416.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Leerink Partners upped their price objective on shares of BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research note on Friday, May 15th. Morgan Stanley reiterated an “overweight” rating and set a $395.00 price objective on shares of BeOne Medicines in a research report on Thursday, May 7th. Finally, Barclays lowered their target price on shares of BeOne Medicines from $409.00 to $403.00 and set an “overweight” rating for the company in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $390.92.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.